CO5580792A2 - Stent o injerto vascular recubierto o impregnado con inhibidores de la proteina tirosina quinasa y metodo de usar el mismo - Google Patents

Stent o injerto vascular recubierto o impregnado con inhibidores de la proteina tirosina quinasa y metodo de usar el mismo

Info

Publication number
CO5580792A2
CO5580792A2 CO04048129A CO04048129A CO5580792A2 CO 5580792 A2 CO5580792 A2 CO 5580792A2 CO 04048129 A CO04048129 A CO 04048129A CO 04048129 A CO04048129 A CO 04048129A CO 5580792 A2 CO5580792 A2 CO 5580792A2
Authority
CO
Colombia
Prior art keywords
vascular
venous
tyrosine kinase
graft
stent
Prior art date
Application number
CO04048129A
Other languages
English (en)
Inventor
Matthew R Wolff
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of CO5580792A2 publication Critical patent/CO5580792A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A61F2/07—Stent-grafts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

1.- Un dispositivo para situar un stent en un vaso sanguíneo, cuyo dispositivo comprende:un stent cardiovascular, un injerto venoso/arterial autólogo, un injerto venoso/arterial prostético, un catéter vascular, o una desviación vascular, teniendo recubierto al mismo, fijado por adsorción, impregnado, o covalente o iónicamente enlazado una cantidad de un inhibidor de la proteína tirosina quinasa; cuya cantidad es suficiente para prevenir o inhibir la proliferación de las células del músculo liso vascular en un área dentro de un vaso sanguíneo inmediatamente adyacente y/o próxima al stent cardiovascular, injerto venoso/arterial autólogo, injerto venoso/arterial prostético, catéter vascular, o desviación vascular, mientras que simultáneamente no inhibe la proliferación de las células íntimas vasculares.2.- El dispositivo de la reivindicación 1, que comprende un stent cardiovascular.3.- El dispositivo de la reivindicación 1, que comprende un injerto autólogo venoso/arterial.4.- El dispositivo de la reivindicación 1, que comprende un injerto prostético venoso/arterial.5.- El dispositivo de la reivindicación 1, que comprende un catéter vascular.6.- El dispositivo de la reivindicación 1, que comprende una desviación vascular.7.- El dispositivo de la reivindicación 1, donde el inhibidor de la proteína tirosina quinasa es un inhibidor del factor de crecimiento derivado de plaquetas.8.- El dispositivo de la reivindicación 7, donde el inhibidor de la proteína tirosina quinasa es también un inhibidor de la tirosina quinasa del Bcr-Abl.9.- El dispositivo de la reivindicación 1, donde el inhibidor de la proteína tirosina quinasa es el STI-571.10.- El dispositivo de la reivindicación 1, donde el inhibidor de la proteína tirosina quinasa es 4-{(4-metil-1-piperazinil)metil}-N-{4-metil-3-{{4-(3-pirimidinil}amino}-fenil}benzamida y/o una sal farmacéuticamente aceptable del mismo; en una cantidad suficiente para prevenir o inhibir la proliferación de las células del músculo liso vascular en un área dentro de un vaso sanguíneo inmediatamente adyacente y/o próxima stent cardiovascular, injerto venoso/arterial autólogo, injerto venoso/arterial prostético, catéter vascular, o desviación vascular.
CO04048129A 2001-10-25 2004-05-25 Stent o injerto vascular recubierto o impregnado con inhibidores de la proteina tirosina quinasa y metodo de usar el mismo CO5580792A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34373201P 2001-10-25 2001-10-25

Publications (1)

Publication Number Publication Date
CO5580792A2 true CO5580792A2 (es) 2005-11-30

Family

ID=23347387

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04048129A CO5580792A2 (es) 2001-10-25 2004-05-25 Stent o injerto vascular recubierto o impregnado con inhibidores de la proteina tirosina quinasa y metodo de usar el mismo

Country Status (18)

Country Link
US (1) US20040044405A1 (es)
EP (1) EP1441749A4 (es)
JP (1) JP2006519623A (es)
KR (1) KR20040051618A (es)
CN (1) CN1635858A (es)
BR (1) BR0213497A (es)
CA (1) CA2464093A1 (es)
CO (1) CO5580792A2 (es)
EC (1) ECSP045085A (es)
HU (1) HUP0402036A3 (es)
IL (1) IL161583A0 (es)
MX (1) MXPA04003906A (es)
NO (1) NO20042133L (es)
NZ (1) NZ532593A (es)
PL (1) PL374315A1 (es)
RU (1) RU2004116068A (es)
WO (1) WO2003034938A2 (es)
ZA (1) ZA200403184B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003232115A1 (en) * 2002-05-13 2003-11-11 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of graft failure
CA2487462C (en) 2002-06-26 2012-05-15 Cook Incorporated Stent-graft fastening
US20050214343A1 (en) * 2002-07-18 2005-09-29 Patrice Tremble Medical devices comprising a protein-tyrosine kinase inhibitor to inhibit restonosis
CA2528032A1 (en) * 2003-06-03 2004-12-16 Beth Israel Deaconess Medical Center Methods and compounds for the treatment of vascular stenosis
WO2005095641A1 (en) * 2004-03-03 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with mitogen-activated protein kinase kinase kinase 11 (map3k11)
KR20070001995A (ko) * 2004-03-05 2007-01-04 리지너크스 바이오 파마소티컬스, 인코포레이티드 세포외 매트릭스 축적의 치료 또는 예방법
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
WO2007033152A2 (en) * 2005-09-12 2007-03-22 Conor Medsystems, Inc. Composition, system and method for modulating release kinetics in implantable drug delivery devices by modifying drug solubility
US20070196428A1 (en) 2006-02-17 2007-08-23 Thierry Glauser Nitric oxide generating medical devices
JP5110559B2 (ja) * 2006-11-24 2012-12-26 学校法人近畿大学 被覆ステント
TW200940527A (en) 2007-12-07 2009-10-01 Vertex Pharma Solid forms of 1-ethyl-3-(5-(5-fluoropyridin-3-yl)-7-(pyrimidin-2-yl)-1H-benzo[d]imidazol-2-yl)urea
EP2285443B1 (en) * 2008-05-01 2016-11-23 Bayer Intellectual Property GmbH Catheter balloon drug adherence techniques and methods
WO2010093889A2 (en) 2009-02-13 2010-08-19 Vertex Pharmaceuticals Incorporated Solid forms of 2-(2, 4-difluorophenyl)-6-(1-(2,6-difluorophenyl)ureido)nicotinamide
US8992601B2 (en) 2009-05-20 2015-03-31 480 Biomedical, Inc. Medical implants
US20110319987A1 (en) 2009-05-20 2011-12-29 Arsenal Medical Medical implant
WO2010135433A1 (en) * 2009-05-20 2010-11-25 Arsenal Medical, Inc. Medical implant
US9265633B2 (en) 2009-05-20 2016-02-23 480 Biomedical, Inc. Drug-eluting medical implants
US9309347B2 (en) 2009-05-20 2016-04-12 Biomedical, Inc. Bioresorbable thermoset polyester/urethane elastomers
US8888840B2 (en) * 2009-05-20 2014-11-18 Boston Scientific Scimed, Inc. Drug eluting medical implant
US8372133B2 (en) * 2009-10-05 2013-02-12 480 Biomedical, Inc. Polymeric implant delivery system
WO2012097273A1 (en) 2011-01-14 2012-07-19 Vertex Pharmaceuticals Incorporated Solid forms of gyrase inhibitor (r)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl) pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1h-benzimidazol-2-yl]urea
US8481551B2 (en) 2011-01-14 2013-07-09 Vertex Pharmaceuticals Incorporated Gyrase and topoisomerase IV inhibitors
US9187953B2 (en) 2011-03-23 2015-11-17 Rytec Corporation Side column configuration for overhead roll-up door assemblies
JP5977344B2 (ja) 2011-06-20 2016-08-24 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ジャイレースおよびトポイソメラーゼ阻害剤のリン酸エステル
US9326951B2 (en) 2011-06-28 2016-05-03 Yale University Cell-free tissue engineered vascular grafts
AR093226A1 (es) 2012-07-18 2015-05-27 Vertex Pharma Formas solidas de dihidrogeno fosfato de (r)-2-(5-(2-(3-etilureido)-6-fluoro-7-(tetrahidrofuran-2-il)-1h-benzo[d]imidazol-5-il)pirimidin-2-il)propan-2-ilo y sus sales
RU2675270C2 (ru) 2013-10-17 2018-12-18 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы и содержащие их фармацевтические композиции
CA3007631A1 (en) 2015-12-11 2017-06-15 Research Institute At Nationwide Children's Hospital Optimized patient specific non-linear tissue engineered vascular grafts
US11628239B2 (en) 2016-11-04 2023-04-18 University Of Delaware Method for protecting skeletonized blood vessels

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4824436A (en) * 1985-04-09 1989-04-25 Harvey Wolinsky Method for the prevention of restenosis
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US6306421B1 (en) * 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5354774A (en) * 1992-12-24 1994-10-11 Yale University Inhibition of smooth muscle cell proliferation by 8-methoxypsoralen photoactivated by visible light
US5279565A (en) * 1993-02-03 1994-01-18 Localmed, Inc. Intravascular treatment apparatus and method
US5788687A (en) * 1994-02-01 1998-08-04 Caphco, Inc Compositions and devices for controlled release of active ingredients
US5788979A (en) * 1994-07-22 1998-08-04 Inflow Dynamics Inc. Biodegradable coating with inhibitory properties for application to biocompatible materials
US6306165B1 (en) * 1996-09-13 2001-10-23 Meadox Medicals ePTFE small caliber vascular grafts with significant patency enhancement via a surface coating which contains covalently bonded heparin
US6245760B1 (en) * 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
CA2332314A1 (en) * 1998-06-11 1999-12-16 Cerus Corporation Use of alkylating compounds for inhibiting proliferation of arterial smooth muscle cells
WO2001060816A1 (en) * 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
US20020156023A1 (en) * 2000-12-06 2002-10-24 Tularik Inc. Lometrexol combination therapy
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins

Also Published As

Publication number Publication date
WO2003034938A3 (en) 2003-11-13
EP1441749A2 (en) 2004-08-04
WO2003034938A2 (en) 2003-05-01
NZ532593A (en) 2007-11-30
ZA200403184B (en) 2005-05-12
EP1441749A4 (en) 2010-05-19
US20040044405A1 (en) 2004-03-04
MXPA04003906A (es) 2005-02-17
CN1635858A (zh) 2005-07-06
IL161583A0 (en) 2004-09-27
RU2004116068A (ru) 2005-03-20
CA2464093A1 (en) 2003-05-01
NO20042133L (no) 2004-07-09
HUP0402036A3 (en) 2008-04-28
BR0213497A (pt) 2006-05-23
HUP0402036A2 (hu) 2005-02-28
PL374315A1 (en) 2005-10-03
ECSP045085A (es) 2004-07-23
JP2006519623A (ja) 2006-08-31
KR20040051618A (ko) 2004-06-18

Similar Documents

Publication Publication Date Title
CO5580792A2 (es) Stent o injerto vascular recubierto o impregnado con inhibidores de la proteina tirosina quinasa y metodo de usar el mismo
DE69942954D1 (de) Endovaskuläre behandlung chronischer venöser insuffizienz
NZ285834A (en) Fms-like tyrosine kinase (flt) and use as an in vitro inhibitor of vascular endothelial growth factor (vegf)
DK1246638T3 (da) Anvendelse af extendiner og agonister deraf til behandlingen af hypertriglyceridæmi
WO2003009779A3 (en) Delivery of therapeutic capable agents
DE60130032D1 (de) Vorrichtung zur Abgabe von therapeutischen Wirkstoffen
Salartash et al. Comparison of open transabdominal AAA repair with endovascular AAA repair in reduction of postoperative stress response
Mii et al. Effect of angiotensin II on human vascular smooth muscle cell growth
Trappanese et al. Regulation of mitogen-activated protein kinase by protein kinase C and mitogen-activated protein kinase phosphatase-1 in vascular smooth muscle
WO2004105684A3 (en) Combination therapy for proliferative disorders
IL148980A0 (en) An antibody to human tissue factor and experimental animals having inserted cells with the gene encoding human tissue factor
CA3035749A1 (en) Femoral and venous arterial cannulas and a method for mitigating the risk of limb ischemia
Xue et al. PU/PTFE-stimulated monocyte-derived soluble factors induced inflammatory activation in endothelial cells
FR2811229B1 (fr) Utilisation d'un polysaccharide excrete par l'espece vibrio diabolicus en cicatrisation osseuse
US20130123306A1 (en) Inhibition of Mitogen-activated Protein Kinases in Cardiovascular Disease
Yamawaki et al. Impairment of EDR by a long-term PDGF treatment in organ-cultured rabbit mesenteric artery
ATE222501T1 (de) Tissue-faktor zur beeinflussung von gefässbildung
Ince et al. Use of a temporary shunt as a salvage technique for distal extremity amputations requiring repair by vessel grafting during critical ischemia
Tsumoto et al. A polyvinyl alcohol core coil containing basic fibroblast growth factor evaluated in rabbits with aneurysms induced by elastase
DE60117762D1 (de) Vitamin d-verbindungen zur behandlung von chronischer tranplantatnephropathie bei nieren transplantieren patienten
AU3461999A (en) Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
Eriksson Adrenergic nerve terminals in collateral arteries of the lower extremity
Cable et al. Gene therapy for vein graft disease
Drummond et al. Contraction of the sheep middle cerebral, pulmonary and coronary arteries initiated by release of intracellular calcium
Conklin et al. Basic fibroblast growth factor coating and endothelial cell seeding of a decellularized vascular graft

Legal Events

Date Code Title Description
FC Application refused